China

Triastek & Lilly to explore the application of 3D printing technology in oral delivery of drugs

According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct ...

 July 14, 2022 | News

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout  and first regulatory approval by the China NMPA in les...

 July 07, 2022 | News

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Chan...

 July 07, 2022 | News

Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs

Enosi Therapeutics, a Delaware Corporation, focused on providing industry-leading therapeutics for cancer and autoimmune diseases, has announced a partners...

 July 06, 2022 | News

WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products

WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG14 fac...

 July 05, 2022 | News

WuXi STA Opens A High-Potency API Plant

The new plant adopts advanced isolation technologies with the capability to handle potent compounds with Occupational Exposure Limit (OEL) as low as 10 ng/...

 June 29, 2022 | News

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

Palleon Pharmaceuticals Inc., a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced a str...

 June 29, 2022 | News

Antengene Announces Clinical Trial Collaboration with BeiGene

Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint inhibitor Antengene Corporation Limited ("...

 June 27, 2022 | News

Mojia Biotech Completes Series B Financing to Advance Manufacturing of Bio-based Materials

Mojia Biotech, a Shanghai-based leading bio-manufacturing company dedicated to sustainable development and carbon neutrality, announced the completion...

 June 23, 2022 | News

META raised 15M USD to accelerate its pipeline development

META Pharmaceuticals, China's first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A fundin...

 June 14, 2022 | News

Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of HBM7008 in patients with soli...

 June 09, 2022 | News

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative im...

 June 07, 2022 | News

CPHI China opens for international partnering after China rises in CPHI Index

 CPHI & P-MEC China opens its online international partnering platform as pharmaceutical and biopharmaceutical industries in the country repo...

 June 06, 2022 | News

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes

WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-...

 June 06, 2022 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close